Pharma Deals Review, Vol 2006, No 71 (2006)

Font Size:  Small  Medium  Large

Novartis Licenses Novel Drug for Hepatitis C Infection

Business Review Editor

Abstract


The youthful antiviral drug discovery company Idenix Pharmaceuticals has licensed its Phase II compound valopicitabine for the treatment of hepatitis C to Novartis in a potential deal value of over US$0.5 B.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.